Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
AstraZeneca announced it has decided to stop the CRESTOR JUPITER clinical study early based on a recommendation from an Independent Data Monitoring Board and the JUPITER Steering Committee, which met on March 29, 2008. The study will be stopped early because there is unequivocal evidence of a reduction in cardiovascular morbidity and mortality amongst patients who received CRESTOR when compared to placebo.
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men 50 years or older, women 60 years or older
Low to normal levels of low density lipoprotein (LDL) cholesterol (\< 130mg/dL)
Elevated levels of C-Reactive Protein (CRP) \> 2.0 mg/L
You may not be if
History of cardiovascular or cerebrovascular events